Johnnie J. Orozco, Ph.D.
Affiliations: | 2004 | University of Washington, Seattle, Seattle, WA |
Area:
ImmunologyGoogle:
"Johnnie Orozco"Parents
Sign in to add mentorPatrick S. Stayton | grad student | 2004 | University of Washington | |
(Characterizing the humoral immune response to human papillomavirus type 6.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Orozco JJ, Vo PT, Gooley TA, et al. (2023) Targeted Radiation Delivery Before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-Term Survivors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
Laszlo GS, Orozco JJ, Kehret AR, et al. (2022) Development of [At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies. Leukemia |
Chow VA, Cassaday RD, Gooley TA, et al. (2021) Mega-dose 90Y-Ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma. Blood Advances |
Orozco JJ, Kenoyer AL, Lin Y, et al. (2020) Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA. Molecular Cancer Therapeutics |
Tuazon SA, Sandmaier BM, Gooley TA, et al. (2020) Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma. Bone Marrow Transplantation |
Matesan MC, Fisher DR, Wong R, et al. (2020) Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry among Hematologic Malignancies. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine |
Gyurkocza B, Nath R, Stiff PJ, et al. (2020) Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial Biology of Blood and Marrow Transplantation. 26 |
Halpern AB, Howard NP, Othus M, et al. (2019) Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm. Leukemia |
Vo P, Gooley TA, Rajendran JG, et al. (2019) Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia. Haematologica |
O'Steen S, Comstock ML, Orozco JJ, et al. (2019) The Alpha Emitter Astatine-211 Targeted to CD38 can Eradicate Multiple Myeloma in a Disseminated Disease Model. Blood |